HK1078021A1 - Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure - Google Patents

Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure

Info

Publication number
HK1078021A1
HK1078021A1 HK05111086A HK05111086A HK1078021A1 HK 1078021 A1 HK1078021 A1 HK 1078021A1 HK 05111086 A HK05111086 A HK 05111086A HK 05111086 A HK05111086 A HK 05111086A HK 1078021 A1 HK1078021 A1 HK 1078021A1
Authority
HK
Hong Kong
Prior art keywords
angiotensin
edema
type
heart failure
congestive heart
Prior art date
Application number
HK05111086A
Other languages
English (en)
Inventor
Harrihar A Pershadsingh
Original Assignee
Bethesda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31721501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1078021(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bethesda Pharmaceuticals Inc filed Critical Bethesda Pharmaceuticals Inc
Publication of HK1078021A1 publication Critical patent/HK1078021A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK05111086A 2002-08-10 2005-12-06 Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure HK1078021A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40242502P 2002-08-10 2002-08-10
US45521103P 2003-03-15 2003-03-15
US10/627,372 US7232828B2 (en) 2002-08-10 2003-07-24 PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
PCT/US2003/024881 WO2004014308A2 (en) 2002-08-10 2003-08-08 Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure

Publications (1)

Publication Number Publication Date
HK1078021A1 true HK1078021A1 (en) 2006-03-03

Family

ID=31721501

Family Applications (2)

Application Number Title Priority Date Filing Date
HK05111086A HK1078021A1 (en) 2002-08-10 2005-12-06 Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure
HK08105223.0A HK1110786A1 (en) 2002-08-10 2008-05-09 Novel ppar ligands that do not cause fluid retention edema or congestive heart failure

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK08105223.0A HK1110786A1 (en) 2002-08-10 2008-05-09 Novel ppar ligands that do not cause fluid retention edema or congestive heart failure

Country Status (15)

Country Link
US (8) US7232828B2 (ko)
EP (6) EP1839660A1 (ko)
JP (3) JP4669285B2 (ko)
KR (4) KR100869450B1 (ko)
CN (6) CN101683528A (ko)
AT (3) ATE487476T1 (ko)
AU (2) AU2003259081B2 (ko)
CA (1) CA2494909C (ko)
DE (2) DE60334942D1 (ko)
DK (2) DK1886683T3 (ko)
ES (2) ES2288631T3 (ko)
HK (2) HK1078021A1 (ko)
MX (1) MXPA05001543A (ko)
PL (1) PL375189A1 (ko)
WO (1) WO2004014308A2 (ko)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
EP1818056A1 (de) * 2003-01-16 2007-08-15 Boehringer Ingelheim International Gmbh Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
DE10319592A1 (de) * 2003-05-02 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Behandlung von diabetischer Retinopathie mit Angiotensin II-Rezeptorblockern
US20040223962A1 (en) * 2003-05-07 2004-11-11 Riordan Neil H. Method and composition for preventing or reducing edema, deep vein thrombosis and/or pulmonary embolism
US20050149174A1 (en) * 2003-12-18 2005-07-07 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
DE102004010194A1 (de) * 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
DE102004010207A1 (de) * 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
CA2583768A1 (en) * 2004-10-07 2006-04-13 Takeda Pharmaceutical Company Limited Agent for prophylaxis or treatment of metabolic syndrome
SI1814527T1 (sl) * 2004-11-05 2014-03-31 Boehringer Ingelheim International Gmbh Dvoslojna tableta, ki obsega telmisartan in amlodipin
US7767682B2 (en) * 2005-03-03 2010-08-03 Glaxosmithkline Llc Medicaments
EP1865778A4 (en) * 2005-03-21 2010-12-08 Metabolex Inc METHOD FOR AVOIDING OEDEM IN THE TREATMENT OF METABOLISM DISORDER, INFLAMMATORY DISEASES AND CARDIOVASCULAR DISEASES
WO2006115185A1 (ja) * 2005-04-21 2006-11-02 Santen Pharmaceutical Co., Ltd. 角結膜障害治療剤
EP1904652A2 (en) * 2005-07-08 2008-04-02 Brystol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
NZ565955A (en) * 2005-08-22 2011-08-26 Melior Pharmaceuticals I Inc Methods and formulations for modulating lyn kinase activity and treating related disorders
ATE526318T1 (de) * 2005-12-19 2011-10-15 Glaxosmithkline Llc Farnesoid-x-rezeptor-agonisten
US20080004281A1 (en) * 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
FR2903984B1 (fr) * 2006-07-24 2008-10-03 Genfit Sa Derives d'imidazolones substitues, preparation et utilisations
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP2125806A1 (en) * 2006-12-21 2009-12-02 Pfizer Products Inc. Compounds having both angiotensin ii receptor antagonism and ppary activating activities
CA2677661A1 (en) * 2007-02-07 2008-08-14 Kyowa Hakko Kirin Co., Ltd. Tricyclic compounds
WO2008096820A1 (ja) * 2007-02-07 2008-08-14 Kyowa Hakko Kirin Co., Ltd. ビフェニル誘導体
CN101686686A (zh) * 2007-02-20 2010-03-31 梅里奥尔医药I公司 鉴别Lyn激酶激活剂的方法
JP5294419B2 (ja) 2007-04-05 2013-09-18 第一三共株式会社 縮合二環式ヘテロアリール誘導体
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) * 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
AU2013202267B2 (en) * 2007-04-11 2015-03-19 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2141989B1 (en) * 2007-04-11 2013-09-11 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
MX2009009693A (es) * 2007-07-23 2009-10-07 Melior Discovery Inc Metodos para activar irs-1 y akt.
CN101396562A (zh) * 2007-09-28 2009-04-01 北京华安佛医药研究中心有限公司 含有arb的组合物在制备治疗高同型半胱氨酸血症损伤及其相关疾病的药物中的用途
CN101959531A (zh) * 2008-02-25 2011-01-26 参天制药株式会社 角膜上皮屏障功能增强剂
AU2009258206B2 (en) * 2008-05-27 2015-07-30 Energesis Pharmaceuticals, Inc. Brown adipocyte progenitors in human skeletal muscle
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
WO2010016549A1 (ja) 2008-08-06 2010-02-11 協和発酵キリン株式会社 ３環系化合物
WO2010065069A2 (en) * 2008-12-01 2010-06-10 In Vasc Therapeutics, Inc. Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
TW201444848A (zh) 2009-01-30 2014-12-01 Takeda Pharmaceutical 稠環化合物及其用途
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
MX2011009244A (es) 2009-03-05 2011-09-26 Daiichi Sankyo Co Ltd Derivado de piridina.
EP3398599A1 (en) * 2009-03-11 2018-11-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20120258170A1 (en) * 2009-05-20 2012-10-11 Nutracryst Therapeutics Private Limited Pharmaceutical co-crystals of quercetin
WO2010133638A1 (de) 2009-05-20 2010-11-25 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische telmisartan-trinklösung
US8951733B2 (en) * 2009-10-16 2015-02-10 Monsanto Technology Llc Methods of polynucleotide detection
EP2311909A1 (de) * 2009-10-16 2011-04-20 Nanoresins AG Hybrid-Partikel von Polymeren und Nanopartikeln
US20130029906A1 (en) * 2009-12-04 2013-01-31 Eric Simard Method of regulating ppar, obesity related pathways and their associated metabolic impact
EP2363119A1 (fr) * 2010-03-05 2011-09-07 Centre Hospitalier Universitaire d'Angers Nouvelle composition pharmaceutique utile pour le traitement des personnes affectées par des maladies neurodégénératives ou neurovasculaires
WO2011150300A1 (en) 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prevention of pancreatic beta cell degeneration
US20120003296A1 (en) * 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
JPWO2012033091A1 (ja) 2010-09-07 2014-01-20 第一三共株式会社 安息香酸エステル類の製造法
US20120156202A1 (en) * 2010-11-05 2012-06-21 Shantha Totada R Age related macular degeneration treatment
WO2012115987A2 (en) * 2011-02-21 2012-08-30 The Trustees Of Columbia University In The City Of New York Methods for Treating and Preventing Cardiac Dysfunction in Septic Shock
US20140147413A1 (en) * 2011-02-28 2014-05-29 Dong Feng Chen Therapies That Target Autoimmunity For Treating Glaucoma And Optic Neuropathy
TW201311678A (zh) * 2011-08-03 2013-03-16 Kyowa Hakko Kirin Co Ltd 二苯并氧呯衍生物
WO2013052965A2 (en) * 2011-10-06 2013-04-11 Miragen Therapeutics Control of whole body energy homeostasis by microrna regulation
CN103372214B (zh) * 2012-04-13 2017-09-29 北京艾棣维欣生物技术有限公司 治疗和/或预防ⅰ型糖尿病的药物组合物及其应用
CN103479627A (zh) * 2013-05-16 2014-01-01 武汉光谷百桥国际生物科技有限公司 一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用
CN107427007B (zh) 2015-02-05 2022-02-11 纪念斯隆凯特林癌症中心 用于治疗水肿的组合物和方法
MX2019012170A (es) 2017-04-10 2020-01-20 Melior Pharmaceuticals I Inc Tratamiento de adipocitos.
WO2021209993A1 (en) * 2020-04-13 2021-10-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of metabolic regulators for the treatment of covid-19
CN114073697B (zh) * 2021-01-19 2023-01-24 复旦大学附属肿瘤医院 Bcat2抑制剂在制备预防和/或治疗bcat2介导的相关代谢疾病药物中的用途

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US283774A (en) 1883-08-28 Cut-off for service-pipes
US5958A (en) * 1848-12-05 Henry ruttan
US402425A (en) 1889-04-30 Wood-grinder for pulp-making
US189514A (en) 1877-04-10 Improvement in street and park lamps
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US4156003A (en) * 1978-08-24 1979-05-22 Ludwig Merckle K.G., Chem. Pharm. Fabrik Treatment of hypertension with combination of clofibrinic acid or clofibrate with cinnarizine
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
DE3928177A1 (de) * 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5817075A (en) * 1989-08-14 1998-10-06 Photogenesis, Inc. Method for preparation and transplantation of planar implants and surgical instrument therefor
US5053420A (en) 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
IL95975A (en) * 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5250554A (en) 1989-10-24 1993-10-05 Takeda Chemical Industries, Ltd. Benzimidazole derivatives useful as angiotensin II inhibitors
ATE169915T1 (de) * 1990-02-15 1998-09-15 Takeda Chemical Industries Ltd Pyrimidindionderivate, deren herstellung und verwendung
US5284661A (en) * 1990-02-22 1994-02-08 Takeda Chemical Industries, Ltd. Fused thiophene derivatives, their production and use
IE910913A1 (en) 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US6004989A (en) * 1990-04-27 1999-12-21 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5703110A (en) 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
DE4023369A1 (de) * 1990-07-23 1992-01-30 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU636066B2 (en) * 1990-10-30 1993-04-08 Takeda Chemical Industries Ltd. Thienoimidazole derivatives, their production and use
US5602127A (en) * 1991-02-06 1997-02-11 Karl Thomae Gmbh (Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists
US5614519A (en) * 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
US5594003A (en) * 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
TW274551B (ko) * 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
IL102365A0 (en) 1991-07-03 1993-01-14 Merck & Co Inc Substituted triazolinones,their preparation and pharmaceutical compositions containing them
EP1000938A1 (en) * 1992-07-03 2000-05-17 Smithkline Beecham Plc Heterocyclic compounds as pharmaceuticals
GB9217820D0 (en) * 1992-08-21 1992-10-07 Fujisawa Pharmaceutical Co New use
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
ATE264323T1 (de) * 1992-09-14 2004-04-15 Takeda Chemical Industries Ltd Heterocyclische verbindungen und ihre verwendung als angiotensin ii antagonisten
US5506245A (en) * 1992-10-12 1996-04-09 Adir Et Compagnie Thiazolidinedione compounds
DE69330593T2 (de) * 1992-12-22 2002-06-27 Takeda Chemical Industries, Ltd. Heterocyclische Verbindungen mit Angiotensin-II-antagonistischer Wirkung und ihre Anwendung
TW268952B (ko) * 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
EP0635263A3 (en) * 1993-06-28 1995-09-27 American Cyanamid Co Angiotensin II antagonists (AII) as inhibitors of the growth of adipose tissue.
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
JPH07138258A (ja) * 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
DE4408497A1 (de) * 1994-03-14 1995-09-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1995026188A1 (en) * 1994-03-29 1995-10-05 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
GB9406573D0 (en) * 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
CA2146701A1 (en) * 1994-04-11 1995-10-12 Takashi Fujita Heterocyclic compounds having anti-diabetic activity, their preparation and their use
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5958942A (en) * 1994-07-15 1999-09-28 Takeda Chemical Industries, Ltd. Tricyclic nitrogen ring compounds, their production and use
CZ261095A3 (en) * 1994-10-07 1996-04-17 Sankyo Co Oxime derivatives, process of their preparation, pharmaceutical composition containing thereof and their use
EP0787725B1 (en) 1994-10-20 2003-04-23 Nippon Chemiphar Co., Ltd. Quinoline derivative
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US5868728A (en) * 1995-02-28 1999-02-09 Photogenesis, Inc. Medical linear actuator for surgical delivery, manipulation, and extraction
US5827865A (en) * 1995-03-09 1998-10-27 Smithkline Beecham P.L.C. Heterocyclic compounds as pharmaceutical
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6022897A (en) * 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5942308A (en) * 1995-07-05 1999-08-24 Nitto Denko Corporation Expandable fixing tape
JPH09176162A (ja) * 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
JP2725665B2 (ja) * 1996-01-29 1998-03-11 日本電気株式会社 プリント配線板製造方法
US6090836A (en) * 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
US6020382A (en) * 1996-02-02 2000-02-01 Merck & Co., Inc. Method of treating diabetes and related disease states
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
KR20050047560A (ko) 1996-04-05 2005-05-20 다께다 케미칼 인더스트리즈,리미티드 안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는약제학적 조합물
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5889032A (en) 1996-05-06 1999-03-30 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
CA2257284C (en) * 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
KR100579765B1 (ko) * 1996-07-01 2006-12-28 닥터 레디스 레보러터리즈 리미티드 신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6160000A (en) 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
US6113907A (en) * 1997-04-15 2000-09-05 University Of Southern California Pharmaceutical grade St. John's Wort
US6011036A (en) * 1997-04-15 2000-01-04 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
US5843172A (en) 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
US6414008B1 (en) * 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
US6011031A (en) * 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
EP1022272B1 (en) * 1997-10-08 2004-05-26 Sankyo Company Limited Substituted fused heterocyclic compounds
US5899032A (en) * 1997-11-14 1999-05-04 Buzby; Edward Stair structure
WO1999025346A1 (en) * 1997-11-19 1999-05-27 Takeda Chemical Industries, Ltd. Novel apoptosis inhibitors
US6008237A (en) 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
CA2318731C (en) * 1998-01-29 2012-05-29 Tularik Inc. Ppar-gamma modulators
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US5945308A (en) * 1998-04-03 1999-08-31 Incyte Pharmaceuticals, Inc. Human oxidized LDL receptor
US6355810B1 (en) * 1998-06-08 2002-03-12 Advanced Medicine, Inc. Multibinding inhibitors of HMG-CoA reductase
US6468996B1 (en) * 1998-10-21 2002-10-22 Novo Nordisk A/S Substituted hetero-polycyclic compounds as PPARα and PPARγ activators
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
US6087385A (en) * 1998-10-30 2000-07-11 University Of Mississippi Flavonoid derivatives
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
ATE261934T1 (de) * 1998-12-16 2004-04-15 Boehringer Ingelheim Pharma Substituierte aryl- und heteroarylamidinderivate, deren herstellung und deren verwendung als arzneimittel
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
US6204288B1 (en) * 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
CA2361998C (en) * 1999-03-12 2009-04-07 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
ID30176A (id) * 1999-03-12 2001-11-08 Boehringer Ingelheim Pharma Senyawa-senyawa yang bermanfaat sebagai zat anti-inflamasi
SE9902597D0 (sv) * 1999-07-06 1999-07-06 Astra Ab New use
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
WO2001025226A1 (en) * 1999-10-05 2001-04-12 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US6451832B2 (en) * 1999-12-23 2002-09-17 Boehringer Ingelheim Pharma Kg Benzimidazoles with antithrombotic activity
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
RU2298418C2 (ru) * 2000-04-12 2007-05-10 Новартис Аг Комбинация по меньшей мере двух соединений, выбранных из групп антагонистов at1-рецептора или ингибиторов асе (ангиотензинпревращающий фермент), или ингибиторов hmg-coa-редуктазы (бета-гидрокси-бета-метилглутарил-кофермент-а-редуктаза)
SK14612002A3 (sk) * 2000-04-12 2003-05-02 Novartis Ag Farmaceutická kompozícia obsahujúca inhibítor aldosterónsyntázy prípadne v kombinácii s antagonistom AT1-receptora a jej použitie
WO2001082858A2 (de) * 2000-05-04 2001-11-08 Ipf Pharmaceuticals Gmbh Neue verbindungen zur behandlung inflammatorischer und kardiovaskulärer erkrankungen
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US6521747B2 (en) 2000-08-28 2003-02-18 Genaissance Pharmaceuticals, Inc. Haplotypes of the AGTR1 gene
US6689385B2 (en) * 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
US20020077348A1 (en) * 2000-11-21 2002-06-20 Dean Herbert M. Dosage unit for cardioprotection
CA2430924A1 (en) * 2000-12-01 2002-06-06 Novartis Ag Angiotensin receptor antagonist composition for the treatment of sexual dysfunction associated with hypertension and another condition
EP1356815A4 (en) * 2001-01-29 2007-03-07 Takeda Pharmaceutical ANALGESIC AND ANTI-INFLAMMATORY DRUGS
ITMI20010203A1 (it) * 2001-02-02 2002-08-02 Solchem Italiana Spa Processo per la preparazione di fibrati
US6527747B2 (en) * 2001-05-25 2003-03-04 Becton Dickinson And Company Introducer needle assembly having a tethered needle shield
CA2459045A1 (en) * 2001-08-31 2003-03-13 Rutgers, The State University Of New Jersey Antidiabetic extracts of artemisia dracunculus
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
EP1818056A1 (de) * 2003-01-16 2007-08-15 Boehringer Ingelheim International Gmbh Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
EP1648515B1 (en) * 2003-07-16 2012-11-21 Boehringer Ingelheim International GmbH Chlorthalidone combinations
BRPI0519656A2 (pt) 2004-12-17 2009-03-03 Boehringer Ingelheim Int terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida
US20060159747A1 (en) * 2004-12-17 2006-07-20 Boehringer Ingelheim International Gmbh Telmisartan and hydrochlorothiazide combination therapy

Also Published As

Publication number Publication date
WO2004014308A2 (en) 2004-02-19
DE60314155D1 (de) 2007-07-12
KR100869449B1 (ko) 2008-11-19
EP1842542A1 (en) 2007-10-10
KR100869450B1 (ko) 2008-11-19
ATE487476T1 (de) 2010-11-15
WO2004014308A3 (en) 2004-08-12
EP1859799B1 (en) 2011-12-07
JP2009235103A (ja) 2009-10-15
CN101683335A (zh) 2010-03-31
KR20050055701A (ko) 2005-06-13
JP2009235102A (ja) 2009-10-15
KR20080005460A (ko) 2008-01-11
CA2494909A1 (en) 2004-02-19
US7867991B2 (en) 2011-01-11
US20070203213A1 (en) 2007-08-30
ATE536183T1 (de) 2011-12-15
AU2009201471A1 (en) 2009-05-07
EP1536785A4 (en) 2005-11-16
CN100548293C (zh) 2009-10-14
DK1536785T3 (da) 2007-09-24
US20080242712A1 (en) 2008-10-02
JP2006515566A (ja) 2006-06-01
CN101683528A (zh) 2010-03-31
KR20080006648A (ko) 2008-01-16
EP1842542A3 (en) 2008-07-16
MXPA05001543A (es) 2005-08-19
US7232828B2 (en) 2007-06-19
EP1536785B1 (en) 2007-05-30
EP1878427A1 (en) 2008-01-16
PL375189A1 (en) 2005-11-28
KR20080065004A (ko) 2008-07-10
CN1688305A (zh) 2005-10-26
US20110046188A1 (en) 2011-02-24
DK1886683T3 (da) 2011-02-21
AU2003259081A1 (en) 2004-02-25
US20070185070A1 (en) 2007-08-09
EP1859799A1 (en) 2007-11-28
ES2288631T3 (es) 2008-01-16
EP1536785A2 (en) 2005-06-08
DE60334942D1 (de) 2010-12-23
DE60314155T2 (de) 2008-01-24
KR100830861B1 (ko) 2008-05-21
CA2494909C (en) 2012-01-10
HK1110786A1 (en) 2008-07-25
CN101683530A (zh) 2010-03-31
US20040127443A1 (en) 2004-07-01
EP1839660A1 (en) 2007-10-03
AU2003259081B2 (en) 2010-03-11
EP1886683B1 (en) 2010-11-10
JP4669285B2 (ja) 2011-04-13
US7812046B2 (en) 2010-10-12
US20070054949A1 (en) 2007-03-08
ATE363277T1 (de) 2007-06-15
EP1886683A1 (en) 2008-02-13
US20080009536A1 (en) 2008-01-10
ES2385936T3 (es) 2012-08-03
CN101683529A (zh) 2010-03-31
CN101683531A (zh) 2010-03-31
US20120094913A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
HK1110786A1 (en) Novel ppar ligands that do not cause fluid retention edema or congestive heart failure
WO2005047244A3 (en) Inhibition of fgfr3 and treatment of multiple myeloma
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
ID26128A (id) Senyawa-senyawa aminotetralin tersubstitusi-n sebagai ligan-ligan untuk reseptor neupeptida y y5 yang bermanfaat dalam pengobatan obesitas dan gangguan-gangguan lain
JP2005518433A5 (ko)
IS8255A (is) P38 kínasatálmar staðsettir á 5 hluta heteróhring
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2002051832A3 (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
UY27689A1 (es) Nuevos derivados de tiazol como antagonistas del receptor npy
EA200501058A1 (ru) Фармацевтическая комбинация из телмисартана и аторвастатина для профилактики или терапевтического лечения сердечно-сосудистых, сердечно-легочных, легочных или почечных заболеваний
DE69431623D1 (de) Hemmung, bekämpfung und regression der angiogenese mit hyaluronsäure oder hyaluronsäure und nsaid
HK1080079A1 (en) A process for the preparation of 2-methylpiperazine derivative
WO2003018515A3 (en) Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
WO2000048446A3 (en) Use of antagonists of pg-e for the treatment of neuropathic pain
WO2003051290A3 (en) Treating b-cell mediated diseases by modulating dr6 activity
IL183564A0 (en) New 3-phenylpropionic acid derivatives and their use as ppar-gamma receptor ligands
ATE289204T1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
DE602006020838D1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
BG103512A (en) Substituted pyramidine compounds and their application
WO2004071152A3 (en) Use of s-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
WO2008016665A3 (en) Imidazoacridine compounds for treating flt3 -mediated disorders
WO2004045283A8 (de) Fungizide mischungen zur bekämpfung von reispathogenen
WO2006124544A3 (en) Use of tyrosine kinase inhibitors in the treatment of metabolic disorders
WO2005110059A3 (en) Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
MA26796A1 (fr) Derive d'aminotetraline pour la therapie des maladies cardiovasculaires.

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230803